摘要
目的:探讨阿格列汀和二甲双胍联合应用对2型糖尿病合并血脂异常患者血糖、血脂指标,以及微量白蛋白尿(MAU)患者糖尿病肾病早期损害指标的影响。方法:90例2糖尿病伴血脂异常患者随机分为3组各30例。M组(含3例MAU患者)予盐酸二甲双胍片500 mg,po,tid;A组(含2例MAU患者)予苯甲酸阿格列汀片25mg,po,qd;M+A组(含3例MAU患者)予盐酸二甲双胍片500 mg,po,tid,联合苯甲酸阿格列汀片25 mg,po,qd。治疗16周后,比较3组患者治疗前后的空腹血糖(FBG)、餐后2 h血糖(2h PBG)、糖化血红蛋白(HbA1c)、总胆固醇(TG)、三酰甘油(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等指标的变化;以及MAU患者尿微量白蛋白(UMalb)与尿肌酐(Ucr)的比值(UACR)。结果:治疗后,3组患者的血糖和血脂指标均较治疗前显著改善(P<0.05)。M+A组治疗后血糖及血脂指标均显著优于M组和A组(P<0.05)。治疗后,3组中MAU患者的UACR均较治疗前有所下降,且M+A组和A组患者的UACR下降更明显。结论:阿格列汀联合二甲双胍明显增强了降糖和降脂作用效果,且能降低2型糖尿病MAU患者的UACR,初步提示了阿格列汀对糖尿病患者肾脏的保护作用。
Objective :To investigate the effect of alogliptin combined with metformin on blood glucose and blood lipid levels in patients with type 2 diabetes mellitus, and preliminary observe the effect of index in microalbuminuria (MAU) patients on early diabetic nephropathy. Methods :90 type 2 diabetes mellitus patients with dyslipidemia were ran- domly divided into three groups ( n = 30). The patients of metformin group ( group M, include 3 MAU patients) were given metformin 500 mg, po, tid. The patients of alogliptin group ( group A, include 2 MAU patients) were given alogliptin 25 mg, po, qd. And the patients of metformin combined with alogliptin group ( group M + A, include 3 MAU patients) were given metformin 500 mg, po, tid combined alogliptin 25 mg, po, qd. The three groups were treated for 16 weeks. The fast- ing blood glucose (FBG), postprandial 2 hours blood glucose (PBG), glycosylated hemoglobin (HbAlc), cholesterol (TG), triglyceride (TC), high-density lipoprotein cholesterol (HDL-C) , low-density lipoprotein cholesterol ( LDL-C ) before and after treatment of three groups, and UACR of the MAU patients in the three groups were compared. Results: The blood glucose, HbAlc and blood lipid indexes of the three groups after treatment were significantly better compared to those before treatment (P 〈 0.05 ). After treatment, compared with the single drug group, the changes of blood glucose and blood lipid index in the M + A group were more obvious (P 〈 0.05 ). After treatment, the UACR of MAU patients in the tree groups were all decreased than before, and in group A and group M + A, the UACR of patients with MAU was decreased more significantly. Conclusion: The effect of alogliptin combined with metformi was obvious in glucose-lowering and lipid-lowering. Alogliptin combined with metformi could reduce the UACR of patients with type 2 diabetes, and preliminarily hint at the protective effects of alogliptin on the kidney of diabetic patients.
作者
王倩
赵可新
李岑
卢丹丹
王声祥
毕长华
Wang Qian;Zhao Kexin;Li Cen;Lu Dandan;Wang Shengxiang;Bi Changhua(Department of Pharmacy;Department of Endocrinology,CNPC Central Hospital,Langfang 065000,Hebei,China)
出处
《药物流行病学杂志》
CAS
2018年第7期438-441,共4页
Chinese Journal of Pharmacoepidemiology
关键词
二甲双胍
阿格列汀
2型糖尿病
微量白蛋白尿
血糖
血脂
Alogliptin
Metformin
Type 2 diabetes mellitus
Microalbuminuria
Blood glucose
Blood lipid